Interview with Jacek Barlinski, Country Manager, Nycomed Poland
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
Address: ul. Kubickiego 11, 02-954 Warszawa ,Poland
Tel: 22 642 07 75
Web: http://www.ranbaxy.com.pl/
The company Ranbaxy began to actively work on the Polish market in 1997. The first products introduced into the pharmaceutical market and achieved huge success. These were the drugs of the fluoroquinolone group: Cifran (Ciprofloxacyna) Zanocin (Oflaxacin) and Norbactin (Norfloxacyna). Based on the success which has had the launch of these drugs, introduced another new product which was Vercef (Cefaclor) – the first on the Polish market, the original generic formulation.
In the following years were registered and placed on the market with more modern antibiotics: Ramoclav (Co-Amoxycilinum) Rantaksym (Cefotaximum) Oframax (Ceftriaxonum). Antibiotics are historically the most important gupę drugs in the portfolio company, which is constantly developed and enriched with new medications, such as: Ceroxim (Cefuroxim axetil); Klabax (claritromycyna) and other
In the first half of 2003 the company started operations in the segment by introducing cardiac preparation Celipres (celiprolol) – betabloker third generation, and in the second half of the product Ramicor (Ramipril) – ACE Inhibitor modern. Both products have met with a very well received by doctors and patients, as confirmed by strong sales of these drugs, which in 2004 amounted to over PLN 2.5 million, in the following year, 2005 – PLN 3.3 million in 2006 – 8.2 million PLN . The portfolio of cardiovascular drugs is still under development and in early 2007, was enriched with the preparation Ranopril (lisinopril) – a drug used among others in leczniu hypertension.
At the end of 2006 the company introduced the sale, preparation called Melobax (Meloxicam) – a modern non-steroidal anti-inflammatory drug. Currently, the drug is used by about 10 000 patients per month.
In mid 2007 the company began selling Ranbaxy formulation Citabax (citalopram) – an antidepressant, an extremely safe activity profile. This product was very well received by doctors and patients. in subsequent years it is planned to introduce further psychiatric drugs.
The beginning of 2008 it also had extensive promotional activities in the segment of gastrointestinal drugs, related to the sale of modern proton pump inhibitor – lansoprazole (trade name Lanbax). This product will be a beginning of the line gastroenterological drugs promoted by the company.
According to IMS data Ranbaxy is 58 among all pharmaceutical companies in Poland. The company is the clear leader of sales growth, which takes place through the introduction of new products and increased sales of existing ones. Systematic increase in sales of Ranbaxy drugs confirms the high quality and high demand among physicians and patients.
The company now operates Ranbaxy 127 people, including 110 persons of field team responsible for maintaining contacts with the medical, aptekarskim and wholesale. Since 2006, the field team is divided into two groups Promo: Rambo 1 (40 representatives) and Rambo 2 (40 representatives). Created in 2008, the third group of promotion – Rambo 3 (20 representatives). All representatives of companies undergoing a very intense and professional training in product knowledge and medical issues with them związnych.
CEPODEM Cefpodoximum Antyinfekcyjny
DOXICIN Doxycyclinum Antyinfekcyjny
NEOPROST Bicalutamid Onkologia
NOBREC Anastrazol Onkologia
VENLABAX Venlafaxyna Psychiatria – leczenie depresji
XETIRAN Fluoxetinum CNS
As we are just starting 2011, could you share with us the results of Nycomed Poland in 2010? In 2010, the affiliate has not been as successful as the previous…
When we look at the full year 2010 unaudited IFRS consolidated sales, we see that Ipsen performed very well in 2010 in Central and Eastern Europe. How has Poland alone…
You joined Eli Lilly Poland in November 2008 as a Marketing Director and you have been leading the affiliate since January 2010. Moreover you are co-chairing the LAWG – Local…
The pharmaceutical industry market growth, including generics and originator drugs, is today steady and sustainable, approximating 10% year on year. The market size is over five billion Euros which makes…
In the pharma world, managers change frequently from one company to another, and this phenomenon has been accelerated with the consolidation of the market, however you chose to dedicate your…
Polski Holding Farmaceutyczny (PHF) was put together in 2004 as a capital group consisting of three leading Polish pharma producers and the mission given by the State Treasury Minister was…
For years Polpharma has been the market leader in Poland. In many countries the arrival of multinational companies (MNCs) led to the loss of leadership by the historical players to…
Unlike many pharmaceutical companies, Servier fully operates in all pharma business activities in Poland: research, drug manufacturing and distribution, and health education. Considering your extensive international and regional experience in…
With the current acquisition of Genzyme by Sanofi-Aventis, the French giant is planning to have Genzyme as a centre of excellence for rare diseases. Genzyme operates in the genetic market,…
Until very recently originator drugs had a very weak presence in central and east European countries including Poland, and there was no real patent legislation. Nevertheless, Poland has changed and…
The group has significantly invested in Poland. Are you today generally satisfied with the initial and follow up investments from Mediq in the country? The group has been present in…
Stretching across the heart of continental Europe, Poland is a massive bridge that links east and west, old and new, and which epitomizes a changing continent. At one time…
See our Cookie Privacy Policy Here